Omeros Corp (OMER)
AI stock analysis · as of Jun 13, 2026
Loading microstructure…
Omeros (OMER) is a clinical-to-commercial-stage biotech that just transformed itself in late 2025: FDA approved YARTEMLEA (narsoplimab) for TA-TMA in December 2025 with sales launching January 2026, and Novo Nordisk paid $240M upfront for zaltenibart (with up to $510M in milestones and $1.3B in sales milestones plus royalties). The core question is whether YARTEMLEA's commercial ramp into ~175 U.S. transplant centers can scale fast enough to service a heavy debt load (~$239M) and justify the equity, against a backdrop of extreme volatility, 23% short interest, and only one sell-side analyst covering the name.
valuationOptically cheap on trailing P/E (7.7x) and PEG (0.81) due to one-time Novo gain distorting EPS, but 64x P/S, negative forward P/E (-291x), and negative book value make traditional multiples unreliable — valuation is really a launch-trajectory call on YARTEMLEA peak sales.
This analysis is from Jun 13, 2026. Want the latest on OMER, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · YARTEMLEA is the only FDA-approved therapy for TA-TMA with a concentrated call point (top 80 of 175 transplant centers do ~80% of procedures), and a permanent CMS reimbursement code was secured in June 2026, removing a key commercial friction point.
- · Novo Nordisk zaltenibart deal delivered $240M cash upfront in November 2025, plus optionality on up to $510M development milestones, $1.3B sales milestones, and high-single to high-teens royalties — meaningful non-dilutive validation from a top-tier partner.
- · Pipeline optionality is real: EMA centralized review for narsoplimab is ongoing, label expansion into ARDS/long COVID is planned, and OncotoX-AML showed 99% selective myeloid progenitor reduction in NHP studies.
- · Trailing P/E of 7.7x and PEG of 0.81 look optically cheap, and EPS of $1.14 reflects gain-on-sale accounting from the Novo deal; if YARTEMLEA ramps, the equity has substantial torque off a $633M market cap.
- · Short interest at 23.3% of float with 10.5 days to cover sets up squeeze potential on positive launch data prints or an EMA approval.
- · Insider net selling over 180 days is $0 (transactions occurred but on a net basis flat), suggesting insiders are not bailing out at these levels.
Bear case
- · No product revenue history — YARTEMLEA launched January 2026 and the next earnings report (Aug 2026) will be the first meaningful read; payer coverage, formulary access, and uptake are still unproven.
- · Balance sheet is fragile: only $9.7M cash at last enumerated reporting period against $239M total debt; the company has historically relied on ATM equity, convertible notes, and asset sales, and 10-K language implies going-concern risk absent the Novo cash.
- · Free cash flow is deeply negative at -$116M, and FY2024 net loss was -$157M; even with the $240M Novo infusion, runway is tight if launch disappoints.
- · Competition from off-label C5 inhibitors (eculizumab, ravulizumab) is entrenched, and a positive ravulizumab Phase 3 in adult TA-TMA would directly threaten YARTEMLEA's monopoly positioning.
- · Single-source manufacturing (Lonza for drug substance, Vetter for fill-finish) with minimum purchase commitments creates supply and cost-overhang risk.
- · Stock dynamics are speculative: a 16% single-session drop in June, only one analyst (HC Wainwright) covering, ~3.6% insider ownership, and price-to-sales of 64x screen as a thinly-followed, retail-driven name.
Catalysts
- · Q2 2026 earnings on August 13, 2026 — first quarter with YARTEMLEA sales; any disclosed launch metrics or revenue print will move the stock materially.
- · EMA decision on narsoplimab MAA for TA-TMA — unlocks European revenue and additional commercial validation.
- · Subsequent CMS/payer coverage expansions and formulary wins at major transplant centers.
- · Zaltenibart development milestone achievements with Novo Nordisk triggering milestone payments (up to $510M cumulative).
- · Phase 2 initiation/data for YARTEMLEA in ARDS/long COVID label expansion.
- · Short squeeze potential: 23.3% short float with 10.5 days to cover means positive launch data could force covering.
Key risks
- · Commercial launch shortfall — slower-than-expected YARTEMLEA uptake would force more dilutive financing given the debt load.
- · Competitive encroachment from ravulizumab in TA-TMA if its Phase 3 reads out positively.
- · Refinancing/dilution risk on the 2029 convertible notes and term loan if cash burn outpaces Novo proceeds.
- · Single-source manufacturing disruption at Lonza or Vetter could halt supply during the critical launch window.
- · Thin analyst coverage (n=1) and high short interest make price discovery noisy and the stock vulnerable to sentiment shifts.
What to watch
- · August 13, 2026 earnings — first YARTEMLEA revenue disclosure and any management commentary on center penetration.
- · EMA decision timing on narsoplimab MAA.
- · Any 8-K disclosures on payer coverage wins or Novo milestone achievements.
- · Cash burn trajectory vs. Novo $240M proceeds — quarterly liquidity updates are critical.
- · Short interest data — sustained >20% short float with positive news flow could trigger a squeeze.
- · Key technical levels: 52-week range of $2.95-$17.65 is wide; watch the $8-9 area as a launch-pad support and prior $12-14 zone as resistance.
Key metrics
Price target rationale
Base case ($14) assumes a modest YARTEMLEA launch trajectory toward ~$150-200M peak U.S. sales potential, valued at ~5-6x forward sales with a discount for execution risk and debt. Bull case ($28) reflects accelerating uptake, EMA approval, and a short-squeeze dynamic — closer to but still below the HC Wainwright $40. Bear case ($4) reflects a launch miss forcing dilutive financing against the $239M debt stack.
On Wall Street's view (mixed): The sole $40 target from HC Wainwright implies ~360% upside and likely reflects a successful peak-sales scenario for YARTEMLEA; the directional bullishness is defensible given commercial monopoly and Novo validation, but the magnitude looks aggressive given debt load, manufacturing risk, and lack of any launch data to underwrite the assumption.
Latest filing (10-K)
Omeros banked $240M from selling zaltenibart to Novo Nordisk and got YARTEMLEA FDA-approved in the same quarter, transforming from a pre-revenue R&D company into a commercial-stage biotech with a debt-heavy balance sheet and a January 2026 product launch to prove out.
Omeros Corporation is a commercial-stage biotechnology company focused on complement-mediated diseases, cancers, and addictive disorders. Its first commercial product, YARTEMLEA (narsoplimab), received FDA approval in December 2025 for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and began generating sales in January 2026. The company also received $240 million upfront in November 2025 from selling exclusive global rights to its MASP-3 inhibitor zaltenibart to Novo Nordisk, with up to $1.8 billion in additional milestones plus tiered royalties eligible.
What the news says · neutral
OMER's dominant storyline centers on the commercial launch of YARTEMLEA (its first-in-class TA-TMA drug) following FDA approval and a $240M Novo Nordisk deal, with a permanent CMS reimbursement code secured in June 2026 representing a meaningful commercial catalyst. However, the stock has shown extreme volatility — surging on positive news only to drop 16% in a single session on June 12, suggesting thin liquidity and speculative trading dynamics rather than steady institutional accumulation. Analyst coverage from HC Wainwright maintains a bullish $40 price target, and the Yartemlea rollout reportedly exceeded early expectations, but sharp intraday reversals and insider selling temper enthusiasm. The net picture is a high-risk, high-reward small-cap biotech with genuine commercial progress but significant execution and volatility risk that makes the stock difficult to hold through the noise.
This analysis is from Jun 13, 2026. Markets move. Get the current read on OMER and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.